Gene therapy developments for pancreatic cancer
Madhumita Bhattacharyya1, Nick R Lemoine
1Centre for Molecular Oncology, Institute of Cancer, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square EC1M 6BQ, London. pompa.bhattacharyya@cancer.org.uk
Abstract:
Treatment options for pancreatic cancer have limited success and it is therefore an appropriate target for the development of new strategies, including gene therapy. Gene therapy approaches include inhibition of activated oncogenes (KRAS, LSM1) with antisense and RNA interference strategies, replacement of inactivated tumour suppressor genes (TP53, CDKN2A, CDKN1A), targeting of cell signalling pathways, gene-directed prodrug-activation therapies and the use of replication-competent oncolytic viruses. Angiogenesis and apoptosis have also been targeted for gene therapy. Clinical trials of gene therapy have shown only moderate anti-tumour effects. As there are many genetic abnormalities in pancreatic cancer, strategies combining different targets or indeed different modalities of treatment, may be more successful. Identification of new targets and improvements in delivery and targeting may further improve the efficacy of gene therapy in pancreatic cancer.
Insights
Gene therapy offers new strategies for pancreatic cancer, targeting oncogenes and tumor suppressors. Combining approaches may improve moderate clinical trial outcomes for this challenging disease.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Pancreatic cancer has limited treatment success, necessitating novel therapeutic strategies.
- Gene therapy presents a promising avenue for addressing the genetic complexities of pancreatic cancer.
Purpose of the Study:
- To review current gene therapy approaches for pancreatic cancer.
- To explore potential strategies for improving gene therapy efficacy.
Main Methods:
- Review of gene therapy strategies including oncogene inhibition (e.g., KRAS, LSM1), tumor suppressor gene replacement (e.g., TP53, CDKN2A, CDKN1A), pathway targeting, gene-directed enzyme prodrug therapy, and oncolytic viruses.
- Discussion of targeting angiogenesis and apoptosis.
- Analysis of clinical trial outcomes.
Main Results:
- Gene therapy approaches show moderate anti-tumor effects in clinical trials.
- Pancreatic cancer exhibits numerous genetic abnormalities, suggesting combination therapies may be beneficial.
Conclusions:
- Combined gene therapy strategies targeting multiple pathways or using different modalities hold potential for enhanced efficacy.
- Further research into novel targets and improved delivery systems is crucial for advancing gene therapy in pancreatic cancer treatment.
Related Concept Videos
00:59Gene Therapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy